

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising the steps of
 - 5 i) contacting a test compound with a AdipoR2 polypeptide,
 - 10 ii) detect binding of said test compound to said AdipoR2 polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising the steps of
 - 15 i) determining the activity of a AdipoR2 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
 - 20 ii) determining the activity of said polypeptide at a different concentration of said test compound.
- 25 3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising the steps of

- i) determining the activity of a AdipoR2 polypeptide at a certain concentration of a test compound,
 - ii) determining the activity of a AdipoR2 polypeptide at the presence of a compound known to be a regulator of a AdipoR2 polypeptide.
- 5
- 4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
- 10 5. The method of any of claims 1 to 3, wherein the cell is in vitro.
- 6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
- 15 7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
- 8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
- 20 9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
- 10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
- 25 11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
- 30 12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular

diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising the steps of

- 5 i) contacting a test compound with a AdipoR2 polynucleotide,
- ii) detect binding of said test compound to said AdipoR2 polynucleotide.
13. The method of claim 12 wherein the nucleic acid molecule is RNA.
- 10
14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
- 15
15. The method of claim 12 wherein the contacting step is in a cell-free system.
16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
- 20
17. The method of claim 12 wherein the test compound is coupled to a detectable label.
- 25
18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising the steps of
 - 30 i) determining the amount of a AdipoR2 polynucleotide in a sample taken from said mammal,

ii) determining the amount of AdipoR2 polynucleotide in healthy and/or diseased mammals.

19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising a therapeutic agent which binds to a AdipoR2 polypeptide.

10

20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising a therapeutic agent which regulates the activity of a AdipoR2 polypeptide.

15

21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising a therapeutic agent which regulates the activity of a AdipoR2 polypeptide, wherein said therapeutic agent is

20

i) a small molecule,

ii) an RNA molecule,

iii) an antisense oligonucleotide,

iv) a polypeptide,

v) an antibody, or

25

vi) a ribozyme.

30

22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising a AdipoR2 polynucleotide.

5

23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising a AdipoR2 polypeptide.

10

24. Use of regulators of a AdipoR2 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal.

15

25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal comprising the steps of

20

25

- i) identifying a regulator of AdipoR2,
- ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases, in a mammal; and

30

- 125 -

iii) combining of said regulator with an acceptable pharmaceutical carrier.

26. Use of a regulator of AdipoR2 for the regulation of AdipoR2 activity in a
5 mammal having a disease comprised in a group of diseases consisting of
cardiovascular diseases, dermatological diseases, gastroenterological diseases,
cancer, hematological diseases, respiratory diseases, inflammation, neuro-
logical diseases, urological diseases.